2
>Wasn't this the exact same problem in US vs Microsooft?
Ye, almost as if this was some sort of time loop, kek
the commentator in that video is kinda like a jack ass.
"oh look, here, our world is really running out of resources, so maybe....maybe...it's the right thing to do"
also
"oh noes, he isn't selfish, he was JUST snitching on them for his family, that's not selfish at all" (yes, it is)
also
"yeah, the network lied to him, but what if they are right and the good guys all along. What Wilson thought he was doing was RIGHTFULLY FOR THE GREATER GOOD"
I mean what the fuck
"greater good", yeah we had that throughout history. It was always psychos.
from /qr/
https://www.news.com.au/lifestyle/health/diet/institute-for-research-in-biomedicine-study-links-palm-oil-to-increased-cancer-risk/news-story/500b5cf5f3bc1c0ebe71802f0e55c643
“Given the prevalence of palm oil as an ingredient in processed foods, this study provides strong motivation for further study on how dietary choices influence the risk of tumour progression.”
Palm oil is a cheap substitute for butter, meaning it is especially common in dough and baked foods. It is commonly found in everyday pantry items, such as margarine, Nutella and biscuits.
Palm oil is a common ingredient in food and cosmetic products, with alternate names such as palm oil kernel, palmitate, palmate, palmitic acid, elaeis guineensis and hydrated palm glycerides hexadecanoic.
https://www.sec.gov/Archives/edgar/data/0001776985/000156459020014536/bntx-20f_20191231.htm#ITEM_3_D
https://archive.md/gH3HE
BioNTech report 2019 to the SEC (Form 20-F)
and I quote:
"No mRNA immunotherapy has been approved, and none may ever be approved. mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of therapeutics."
"Currently,mRNA is considered a gene therapy product by the FDA."
"In addition, even if we successfully advance one of our product candidates into and through clinical trials, such trials will likely only include a limited number of subjects and limited duration of exposure to our product candidates.As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of patients are exposed to the product candidate. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period."